FASLODEX Drug Insight and Market Forecast - 2032

“FASLODEX Drug Insight and Market Forecast - 2032” report provides comprehensive insights about FASLODEX for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the FASLODEX for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the FASLODEX for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FASLODEX market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.

Drug Summary

FASLODEX (fulvestrant) is an estrogen receptor antagonist used for the treatment of hormone-receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The generics of FASLODEX has entered the US market in 2019.

It is used alone as the first treatment for postmenopausal women diagnosed with hormone-receptor-positive, HER2−negative, advanced-stage breast cancer that has not been treated with hormonal therapy. FASLODEX is the only Estrogen receptors downregulators (ERD) available to treat breast cancer.

Dosage and Administration

• The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1-2 min per injection) as two 5 mL injections, one in each buttock, on days 1, 15, 29, and once monthly thereafter.
• A dose of 250 mg is recommended in patients with moderate hepatic impairment to be administered intramuscularly into the buttock (gluteal area) slowly (1-2 min) as one 5 mL injection on Days 1, 15, 29, and once monthly thereafter.

Mechanism of Action

It is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with an affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.

Fulvestrant is a reversible inhibitor of the growth of tamoxifen-resistant, as well as estrogen-sensitive human breast cancer (MCF-7) cell lines.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the FASLODEX description, mechanism of action, dosage and administration, research and development activities in ER+ve HER2-ve Breast Cancer.
• Elaborated details on FASLODEX regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FASLODEX research and development activity in ER+ve HER2-ve Breast Cancer in detail across the United States.
• The report also covers the patents information with expiry timeline around FASLODEX.
• The report contains forecasted sales of FASLODEX for ER+ve HER2-ve Breast Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ER+ve HER2-ve Breast Cancer.
• The report also features the SWOT analysis with analyst views for FASLODEX in ER+ve HER2-ve Breast Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FASLODEX Analytical Perspective

In-depth FASLODEX Market Assessment

This report provides a detailed market assessment of FASLODEX in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

FASLODEX Clinical Assessment

The report provides the clinical trials information of FASLODEX in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for ER+ve HER2-ve Breast Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FASLODEX dominance.
• Other emerging products for ER+ve HER2-ve Breast Cancer are expected to give tough market competition to FASLODEX and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FASLODEX in ER+ve HER2-ve Breast Cancer.
• This in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FASLODEX in ER+ve HER2-ve Breast Cancer.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of FASLODEX?
• What is the clinical trial status of the study related to FASLODEX in ER+ve HER2-ve Breast Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FASLODEX development?
• What are the key designations that have been granted to FASLODEX for ER+ve HER2-ve Breast Cancer?
• What is the forecasted market scenario of FASLODEX for ER+ve HER2-ve Breast Cancer?
• What are the forecasted sales of FASLODEX in the United States?
• What are the other emerging products available in ER+ve HER2-ve Breast Cancer and how are they giving competition to FASLODEX for ER+ve HER2-ve Breast Cancer?
• Which are the late-stage emerging therapies under development for the treatment of ER+ve HER2-ve Breast Cancer?

This product will be delivered within 2 business days.